Checkpoint Therapeutics: Key Governance and Growth Decisions Approved

TipRanksMay 14 19:42

Checkpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

Checkpoint Therapeutics, Inc. ("Checkpoint") (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ, taking place on Monday, May 20, 2024, at 12:30 p.m. ET. Checkpoint will also attend in-person one-on-one meetings during the conference.

Fortress Biotech Inc Series A PMay 13 12:00

Checkpoint Therapeutics First Quarter 2024 Earnings: US$0.32 Loss per Share (Vs US$0.89 Loss in 1Q 2023)

Yahoo FinanceMay 12 21:54

Checkpoint Therapeutics | 10-Q: Quarterly report

Futu NewsMay 11 04:24 · Announcements

Checkpoint Therapeutics (CKPT.US): The 2024 Q1 financial report achieved revenue of $0, previous value of USD 35,000, expected value of USD 10,000; earnings per share were -0.33 USD, previous value was -0.89 USD, and expected value was -0.27 USD.

Checkpoint Therapeutics (CKPT.US): The 2024 Q1 financial report achieved revenue of $0, previous value of USD 35,000, expected value of USD 10,000; earnings per share were -0.33 USD, previous value was -0.89 USD, and expected value was -0.27 USD.

Zhitong FinanceMay 10 21:50

Checkpoint Therapeutics Q1 EPS $(0.33) Misses $(0.27) Estimate

Checkpoint Therapeutics (NASDAQ:CKPT) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimate of $(0.27) by 22.22 percent. This is a 62.92 percent increase over loss

BenzingaMay 10 20:33